RadNet acquires AI firms Aidence and Quantib for ~$95M combined; issues 2.1M shares

RadNet, Inc.

Aidence acquired for ~$50M (incl. $10M milestones); Quantib for ~$45M.
Issued 1,141,234 shares for Aidence and 965,058 shares for Quantib to stakeholders.
Adds AI for lung nodule (Aidence) and prostate/brain MRI (Quantib) to DeepHealth division.
Quantib products have FDA 510(k) clearance; Aidence's Veye pending FDA approval.
Dr. Gregory Sorensen to lead combined AI initiatives across all three entities.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.